{'52WeekChange': -0.028859496,
 'SandP52WeekChange': 0.0644362,
 'address1': '6400 Westwind Way',
 'address2': 'Suite A',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 27.97,
 'askSize': 800,
 'averageDailyVolume10Day': 1005750,
 'averageVolume': 934147,
 'averageVolume10days': 1005750,
 'beta': 1.259536,
 'beta3Year': None,
 'bid': 27.94,
 'bidSize': 800,
 'bookValue': 3.434,
 'category': None,
 'circulatingSupply': None,
 'city': 'Crestwood',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 28.9,
 'dayLow': 27.82,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -4.798,
 'enterpriseToRevenue': None,
 'enterpriseValue': 1621074816,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 31.686142,
 'fiftyTwoWeekHigh': 45.04,
 'fiftyTwoWeekLow': 16.85,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 54966714,
 'forwardEps': -5.7,
 'forwardPE': -4.9,
 'fromCurrency': None,
 'fullTimeEmployees': 266,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.21841998,
 'heldPercentInstitutions': 0.69478995,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/apellis.com',
 'longBusinessSummary': 'Apellis Pharmaceuticals, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on the development '
                        'of therapeutic compounds through the inhibition of '
                        'the complement system for autoimmune and inflammatory '
                        'diseases. Its lead product candidate is APL-2 that is '
                        'in Phase III clinical trials for the treatment of '
                        'geographic atrophy in age-related macular '
                        'degeneration and paroxysmal nocturnal hemoglobinuria '
                        'diseases; and in Phase II clinical trials for the '
                        'treatment of cold agglutinin and warm antibody '
                        'autoimmune hemolytic anemia diseases, as well as in '
                        'Phase II clinical trials to treat four types of '
                        'glomerular diseases, such as C3 glomerulopathy, IgA '
                        'nephropathy, primary membranous nephropathy, and '
                        'lupus nephritis. The company is also developing '
                        'APL-9, which is in single ascending dose Phase I '
                        'randomized, double-blind, and placebo-controlled '
                        'clinical trials for intravenous administration in '
                        'systemic indications. It has a risk-sharing '
                        'collaboration agreement with SFJ Pharmaceuticals '
                        'Group for the development of APL-2 in hematologic '
                        'indications. Apellis Pharmaceuticals, Inc. was '
                        'founded in 2009 and is headquartered in Crestwood, '
                        'Kentucky.',
 'longName': 'Apellis Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 2109080960,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_106524288',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -422954624,
 'nextFiscalYearEnd': 1640908800,
 'open': 28.9,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -1.62,
 'phone': '502 241 4114',
 'previousClose': 29.3,
 'priceHint': 2,
 'priceToBook': 8.133372,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 28.9,
 'regularMarketDayLow': 27.82,
 'regularMarketOpen': 28.9,
 'regularMarketPreviousClose': 29.3,
 'regularMarketPrice': 28.9,
 'regularMarketVolume': 731900,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 75499200,
 'sharesPercentSharesOut': 0.1277,
 'sharesShort': 9641815,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 8157840,
 'shortName': 'Apellis Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.19600001,
 'shortRatio': 10,
 'startDate': None,
 'state': 'KY',
 'strikePrice': None,
 'symbol': 'APLS',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -6.391,
 'twoHundredDayAverage': 33.60831,
 'volume': 731900,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.apellis.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '40014'}